SOURCE: Novo Nordisk A/S

February 22, 2010 08:56 ET

Transaction in Own Shares

BAGSVAERD, DENMARK--(Marketwire - February 22, 2010) - Novo Nordisk A/S - Share repurchase programme

On 2 February 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010.


Since the announcement as of 15 February 2010, the following transactions have been made under the programme:

                            Number of         Average          Transaction
                             shares        purchase price      value, DKK

 Accumulated, last
 Announcement                885,000                           331,984,754

 15 February 2010             75,000          391.0200          29,326,500

 16 February 2010             90,000          391.3800          35,224,200

 17 February 2010             90,000          392.8600          35,357,400

 18 February 2010             75,000          393.4850          29,511,375

 19 February 2010             90,000          394.1670          35,475,030

 Accumulated under the
 Programme                 1,305,000                           496,879,259

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 125,650 B shares in the period from 15 February 2010 to 19 February 2010. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 31,576,298 treasury shares, corresponding to 5.1% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:

Media:                                  Investors:

Mette Kruse Danielsen                   Klaus Bülow Davidsen
Tel: (+45) 4442 3883                    Tel: (+45) 4442 3176
mkd@novonordisk.com                     klda@novonordisk.com

                                        Kasper Roseeuw Poulsen
                                        Tel: (+45) 4442 4471
                                        krop@novonordisk.com

In North America:                       In North America:
Sean Clements                           Hans Rommer
Tel: (+1) 609 514 8316                  Tel: (+1) 609 919 7937
secl@novonordisk.com                    hrmm@novonordisk.com

Company Announcement no 10 / 2010

[HUG#1387085]

Company Announcement no 10 2010: http://hugin.info/2013/R/1387085/345487.pdf

Contact Information